An experimental coronavirus vaccine being developed by pharmaceutical giant Pfizer and the German firm BioNTech triggered stronger immune responses in recipients than those seen in people recovering from a natural infection in a small study published online Wednesday.
Publisher: Washington Post | Author: Carolyn Y Johnson